Ontology highlight
ABSTRACT:
SUBMITTER: Pinto A
PROVIDER: S-EPMC3586060 | biostudies-other | 2012 Dec
REPOSITORIES: biostudies-other
Drugs in R&D 20121201 4
In the last few years, the treatment of castration-resistant prostate carcinoma (CRPC) has changed completely. The approval of docetaxel and subsequent investigation in this field have led to development of new agents that have demonstrated an improvement in overall survival in the post-docetaxel setting, such as cabazitaxel and abiraterone. Radium-223 chloride is a radioisotope that has recently shown efficacy after docetaxel and in patients unfit for docetaxel, with improvements in overall sur ...[more]